These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 20218215)

  • 1. [Pharmacotherapy in the treatment of borderline personality disorder].
    Alliani D; Tarantelli S
    Riv Psichiatr; 2009; 44(6):357-73. PubMed ID: 20218215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aripiprazole pharmacotherapy of borderline personality disorder.
    Mobascher A; Mobascher J; Schlemper V; Winterer G; Malevani J
    Pharmacopsychiatry; 2006 May; 39(3):111-2. PubMed ID: 16721700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study.
    Nickel MK; Muehlbacher M; Nickel C; Kettler C; Pedrosa Gil F; Bachler E; Buschmann W; Rother N; Fartacek R; Egger C; Anvar J; Rother WK; Loew TH; Kaplan P
    Am J Psychiatry; 2006 May; 163(5):833-8. PubMed ID: 16648324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aripiprazole treatment of patients with borderline personality disorder.
    Nickel MK
    J Clin Psychiatry; 2007 Nov; 68(11):1815-6. PubMed ID: 18052583
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of aripiprazole in treatment of cannabis dependence in a patient presenting with Borderline Personality Disorder.
    Geoffroy PA; Rolland B; Guardia D; Warembourg F; Cottencin O
    J Neuropsychiatry Clin Neurosci; 2012; 24(2):E37. PubMed ID: 22772696
    [No Abstract]   [Full Text] [Related]  

  • 6. Aripiprazole in a therapy-resistant patient with borderline personality and post-traumatic stress disorder.
    Kellner M
    Pharmacopsychiatry; 2007 Jan; 40(1):41. PubMed ID: 17327963
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy and tolerability of pharmacotherapies for borderline personality disorder.
    Bellino S; Paradiso E; Bogetto F
    CNS Drugs; 2008; 22(8):671-92. PubMed ID: 18601305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of aripiprazole augmentation in sertraline-resistant patients with borderline personality disorder.
    Bellino S; Paradiso E; Bogetto F
    Psychiatry Res; 2008 Nov; 161(2):206-12. PubMed ID: 18848360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacological treatment for patients with borderline personality disorder: practice and study results].
    Schwerthöffer D; Bäuml J; Rentrop M
    Fortschr Neurol Psychiatr; 2013 Aug; 81(8):437-43. PubMed ID: 23939557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The value of psychopharmacotherapy in the treatment of borderline personality disorder].
    Leitner P; Serfling R
    Psychiatr Prax; 1993 Nov; 20(6):207-10. PubMed ID: 7906044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aripiprazole in treatment of borderline patients, part II: an 18-month follow-up.
    Nickel MK; Loew TH; Pedrosa Gil F
    Psychopharmacology (Berl); 2007 May; 191(4):1023-6. PubMed ID: 17318503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacotherapy of the borderline patient: a critical review and clinical guidelines.
    Kutcher SP; Blackwood DH
    Can J Psychiatry; 1989 May; 34(4):347-53. PubMed ID: 2567621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacotherapy effectiveness for some symptoms of borderline personality disorder].
    Benjaminsen S
    Ugeskr Laeger; 2014 Sep; 176(36):. PubMed ID: 25293847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical potentialities and perspectives for the use of aripiprazole in other disorders than its classical indications. A critical analysis of the recent literature].
    Crocq MA; Camus V; Millet B; Gliskman J; Azorin JM; Krebs MO; Limosin F; Costentin J; Daléry J
    Encephale; 2008 Apr; 34(2):187-93. PubMed ID: 18597728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacological treatment of borderline personality disorder].
    Mazaira S
    Vertex; 2004 Dec-2005 Feb; 15(58):303-8. PubMed ID: 15597127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging evidence for the use of atypical antipsychotics in borderline personality disorder.
    Grootens KP; Verkes RJ
    Pharmacopsychiatry; 2005 Jan; 38(1):20-3. PubMed ID: 15706462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of pharmacological treatments and real-world outcomes in borderline personality disorder.
    Lieslehto J; Tiihonen J; Lähteenvuo M; Mittendorfer-Rutz E; Tanskanen A; Taipale H
    Acta Psychiatr Scand; 2023 Jun; 147(6):603-613. PubMed ID: 37094828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Considerable improvement in a case of obsessive-compulsive disorder in an emotionally unstable personality disorder, borderline type under treatment with clozapine.
    Steinert T; Schmidt-Michel PO; Kaschka WP
    Pharmacopsychiatry; 1996 May; 29(3):111-4. PubMed ID: 8738316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorder.
    Taneja C; Papakostas GI; Jing Y; Baker RA; Forbes RA; Oster G
    Ann Pharmacother; 2012 May; 46(5):642-9. PubMed ID: 22550279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A naturalistic study of changes in pharmacological prescription for borderline personality disorder in clinical practice: from APA to NICE guidelines.
    Pascual JC; Martín-Blanco A; Soler J; Ferrer A; Tiana T; Alvarez E; Pérez V
    Int Clin Psychopharmacol; 2010 Nov; 25(6):349-55. PubMed ID: 20838221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.